![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
HIV-1 Attachment Inhibitor Prodrug BMS-663068: Assessment of Interactions with Raltegravir in Treatment-Experienced HIV-1-Infected Subjects & Efficacy/Safety
|
|
|
Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; May 26-28, 2015; Washington, DC, USA.
I Landry,1 D Cui,2 J Wang,1 M Lataillade,3 DW Boulton1
CROI: 48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation - (03/03/15)
CROI: Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 48 Analysis - (02/27/15)
CROI: HIV-1 Attachment Inhibitor Prodrug BMS-663068: Interactions with DRV/r and/or ETR - (02/26/15)
CROI: HIV-1 Attachment Inhibitor Prodrug BMS-663068: Pharmacokinetics, Pharmacodynamics and Model-Based Dose Selection - (02/26/15)
CROI: BMS-955176: Antiviral Activity and Safety of a Second-Generation HIV-1 Maturation Inhibitor - (02/27/15)
CROI: Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in Preventing Viral Replication via Different Mechanism of Action Than Current Therapies - (02/27/15)
IDSA/2014: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis.......http://www.natap.org/2014/IDSA/IDSA_08.htm
Glasgow/2014: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis and Safety Profile - oral presentation......http://www.natap.org/2014/GLASGOW/GLASGOW_16.htm
HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Primary Week 24 Analysis of Emergent Drug Resistance.....http://www.natap.org/2014/ResisWksp/ResisWksp_08.htm
Glasgow/2014: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis.....http://www.natap.org/2014/GLASGOW/GLASGOW_17.htm
Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis......http://www.natap.org/2014/GLASGOW/GLASGOW_13.htm
Early studies - Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects.......http://www.natap.org/2012/HIV/090712_02.htm
![pharm1.gif](../images/060215/060215-7/pharm1.gif)
![pharm2.gif](../images/060215/060215-7/pharm2.gif)
![pharm3.gif](../images/060215/060215-7/pharm3.gif)
![pharm4.gif](../images/060215/060215-7/pharm4.gif)
![pharm5.gif](../images/060215/060215-7/pharm5.gif)
![pharm6.gif](../images/060215/060215-7/pharm6.gif)
![pharm7.gif](../images/060215/060215-7/pharm7.gif)
![pharm8.gif](../images/060215/060215-7/pharm8.gif)
![pharm9.gif](../images/060215/060215-7/pharm9.gif)
![pharm10.gif](../images/060215/060215-7/pharm10.gif)
![Ref.gif](../images/060215/060215-7/Ref.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|